Adilip-135 activates PPAR-α receptors involved in lipid metabolism, effectively lowering triglycerides and LDL cholesterol, while increasing HDL cholesterol.
Recommended for:
Patients with primary or mixed dyslipidemia
Those with metabolic syndrome
Cardiovascular risk prevention
Combination therapy (under medical supervision)
Treatment of primary hyperlipidemia (Type IIa and IIb), hypertriglyceridemia (Type IV), and mixed dyslipidemia in adults.
Take one tablet daily with food. Duration and monitoring should be determined by a healthcare professional based on lipid profile and patient response.
Hypersensitivity to fenofibrates
Liver or gallbladder disease
Severe renal impairment
Pregnancy and breastfeeding
Possible side effects: digestive disturbances, muscle pain, allergic reactions, increased liver enzymes, photosensitivity
